Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Gynecologic Oncology
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
•
Primary Care
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?
Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?
How do you treat ER/PR + DCIS with no identified invasive component that has microscopic sentinel lymph node metastasis? Would you complete HER2 staining on original specimen?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
